AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 228.31

Change

-15.77 (-6.46)%

Market Cap

USD 140.24B

Volume

6.93M

Avg Analyst Target

USD 254.91 (+11.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. It also has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

-0.35 (-0.61%)

USD179.59B 40.17 21.72
SNY Sanofi

-1.62 (-3.15%)

USD129.27B 18.83 12.92
GILD Gilead Sciences, Inc

-0.59 (-0.84%)

USD87.58B 17.09 14.24
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

+0.10 (+0.03%)

USD50.37B 27.03 14.69
HZNP Horizon Therapeutics Public Li..

+7.75 (+7.77%)

USD22.42B 79.74 40.15
GRFS Grifols, S.A

+0.04 (+0.26%)

USD14.87B 26.43 15.93
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+5.86 (+2.77%)

USD0.57B
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.00 %

+0.02 (+0.13%)

N/A
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

+0.17 (+3.19%)

USD0.48B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.24%)

USD0.04B
CIND:LSE iShares VII Public Limite.. 0.00 % 0.33 %

-1.05 (-0.26%)

USD0.86B
IHCU:LSE iShares V Public Limited .. 0.00 % 0.15 %

+4.75 (+0.66%)

USD1.69B
SBUY:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

+19.00 (+0.53%)

USD0.07B
UC46:LSE UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

+27.00 (+0.20%)

USD1.92B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
BUYB:PA Invesco Markets III plc -.. 0.00 % 0.39 %

+0.24 (+0.57%)

USD0.07B
EKUS:PA BNP Paribas Easy - MSCI U.. 0.00 % 0.00 %

+0.05 (+0.31%)

USD0.36B
3SUR:F iShares IV Public Limited.. 0.00 % 0.23 %

+3.40 (+0.21%)

N/A
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

+0.12 (+0.28%)

USD0.07B
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.51 %

-0.60 (-0.20%)

USD6,289.39B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.65 (+0.72%)

USD0.39B
SXRU:F iShares VII Public Limite.. 0.00 % 0.33 %

+0.65 (+0.19%)

USD0.86B
UIMP:F UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

+0.30 (+0.19%)

USD1.92B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.21 (+3.36%)

USD0.40B
BBCK:XETRA Invesco Markets III plc -.. 0.00 % 0.39 %

+0.23 (+0.55%)

USD0.07B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.51 %

-0.45 (-0.15%)

USD6,289.39B
MJMT:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.73 (+0.81%)

USD0.46B
SXRU:XETRA iShares VII Public Limite.. 0.00 % 0.33 %

-0.60 (-0.18%)

USD0.86B
UEFY:XETRA UBS ETF SICAV - SBI Forei.. 0.00 % 0.20 %

-0.01 (-0.09%)

USD0.19B
UET1:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

+0.03 (+0.12%)

USD0.15B
UIMP:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

+0.50 (+0.32%)

USD1.92B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.28%)

USD0.48B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

-0.17 (-0.17%)

USD0.51B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+2.88 (+2.83%)

USD0.27B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.05 (+0.38%)

USD1.19M
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.45 (-2.58%)

USD9.12M
BLV Vanguard Long-Term Bond I.. 0.00 % 0.05 %

+0.20 (+0.19%)

USD11.04B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

-1.30 (-1.74%)

USD0.49B
DIA SPDR Dow Jones Industrial.. 0.00 % 0.16 %

-3.10 (-0.88%)

USD30.46B
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

-0.54 (-1.21%)

USD0.17B
IBB iShares Biotechnology ETF 0.00 % 0.46 %

+2.75 (+1.62%)

USD10.82B
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

+0.03 (+0.05%)

USD0.77B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

+0.36 (+0.47%)

USD0.30B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.35 (-0.43%)

USD0.37B
RSP Invesco S&P 500 Equal Wei.. 0.00 % 0.20 %

-1.45 (-0.94%)

USD28.55B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.05 (+0.38%)

USD1.19M
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.06 %

-0.97 (-1.26%)

USD26.00B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
UDOW ProShares Trust - ProShar.. 0.00 % 0.95 %

-2.09 (-2.72%)

USD1.06B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

-0.59 (-0.23%)

USD17.94B
VVO:CA Vanguard Global Minimum V.. 0.00 % 0.36 %

-0.08 (-0.23%)

USD0.05B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.26 %

-0.44 (-0.78%)

USD0.32B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.72 %

-0.22 (-0.81%)

USD0.22B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

-0.06 (-0.69%)

USD0.33B
EDOW First Trust Dow 30 Equal .. 0.00 % 0.50 %

-0.29 (-0.93%)

USD0.11B
VALQ American Century ETF Trus.. 0.00 % 0.29 %

-0.37 (-0.73%)

USD0.24B
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.70% 29% F 37% F
Dividend Return 1.53% 20% F 56% F
Total Return 0.83% 29% F 39% F
Trailing 12 Months  
Capital Gain -5.45% 29% F 21% F
Dividend Return 2.78% 40% F 50% F
Total Return -2.67% 29% F 22% F
Trailing 5 Years  
Capital Gain 31.47% 71% C- 46% F
Dividend Return 15.89% 60% D- 63% D
Total Return 47.36% 71% C- 49% F
Average Annual (5 Year Horizon)  
Capital Gain 10.89% 71% C- 54% F
Dividend Return 2.97% 60% D- 72% C-
Total Return 13.86% 71% C- 58% F
Risk Return Profile  
Volatility (Standard Deviation) 11.96% 86% B 89% B+
Risk Adjusted Return 115.87% 86% B 96% A
Market Capitalization 140.24B 86% B 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.22 71% C- 45% F
Price/Book Ratio 14.87 14% F 9% F
Price / Cash Flow Ratio 13.36 71% C- 30% F
EV/EBITDA 12.65 100% A+ 61% D-
Management Effectiveness  
Return on Equity 75.30% 100% A+ 99% A+
Return on Invested Capital 20.18% 100% A+ 89% B+
Return on Assets 9.16% 86% B 92% A-
Debt to Equity Ratio 349.61% 14% F 5% F
Technical Ratios  
Short Ratio 4.42 43% F 29% F
Short Percent 1.80% 43% F 66% D
Beta 0.71 29% F 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector